Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Improving Your Bottom Line: Mid Year Analysis Vital to Practice
Owen Dahl, Owen Dahl Consulting
FDA Update: Immune Response Robustness Correlates with Survival in Brain Cancer Vaccine Trial
Tracy Hampton, PhD, MDLinx Oncology
  See all
glioblastoma multiforme Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection
Journal of Neuro-Oncology, 05/15/08
Print     Email This Article     Save in My Library   Free Abstract
Chaichana KL et al. - In a study to determine if glioblastoma multiforme (GBM) bordering the lateral ventricles (LV) was associated with decreased survival as compared with non-LV GBM, it was found that while the causal factors underlying this observation are not provided with this observational study, GBM bordering the LV may carry a prognostic significance

Methods
  • Clinical records of 69 consecutive pts undergoing craniotomy for GBM were reviewed
  • 26 pts were identified with contrast-enhancing lesions (CEL) bordering the LV (LV CEL)
  • These 26 pts were matched with 26 pts with CEL not bordering the LV (non-LV CEL)
  • Cohorts were matched for age, tumor size, Karnofsky performance score, extent of resection, Gliadel implantation, and Temodar chemotherapy

Results
  • Despite similarities in pre-operative clinical status, tumor size, peri-operative outcome, and treatment regimens, median survival for pts with LV CEL was significantly decreased vs pts with non-LV CEL
  • Survival analysis in pts stratified by primary and secondary resection demonstrated a strong trend toward decreased survival after resection of LV CEL
  • After primary and secondary resection, pts with LV CEL vs non-LV CEL had a median survival of 11 months vs 14 months and 7 months vs 10 months, respectively

 

Sponsor
--- NEUROLOGIC ONCOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.